Today, a Director at Agile Therapeutics (AGRX), Abhijeet Lele, bought shares of AGRX for $30.8K.
Following this transaction Abhijeet Lele’s holding in the company was increased by 111.43% to a total of $57.3K. This is Lele’s first transaction since reporting a Buy transaction on STXS back in November 2008
See today’s analyst top recommended stocks >>
Currently, Agile Therapeutics has an average volume of 269.9K.
Based on 4 analyst ratings, the analyst consensus is Strong Buy with an average price target of $2.86, reflecting a 93.2% upside. Three different firms, including Guggenheim and Maxim Group, currently also have a Buy rating on the stock.
The insider sentiment on Agile Therapeutics has been positive according to 14 insider trades in the past three months. This sentiment is slightly higher than the average sentiment of company insiders in this sector.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Agile Therapeutics, Inc. is a healthcare company, which engages in the development and commercialization of transdermal patch. Its lead product candidate, Twirla, also known as AG200-15, is an investigational low-dose, non-daily prescription contraceptive. The company was founded by Chien Te Yen on December 22, 1997 and is headquartered in Princeton, NJ.
